haemophilia Archives -

Market Access/ News/ News/ News/ Sales and Marketing

uniQure, CSL claim first okay for haemophilia B gene therapy

Phil Taylor CSL, gene therapy, Haematology, haemophilia, haemophilia B, Hemgenix, regulatory approval, uniQure 0 Comment

uniQure and CSL have become the first pharma companies to get regulatory approval for a gene therapy for

uniQure, CSL claim first okay for haemophilia B gene therapy

https://pharmaphorum.com/news/uniqure-csl-claim-first-okay-for-a-haemophilia-b-gene-therapy/

Insights/ Insights/ Patients/ R&D/ Views and analysis

Capturing progress in haemophilia care

mike.hammerton@pharmaphorum.com disease awareness, haemophilia, healthcare, patient advocacy, patient experience, Portraits of Progress, R&D 0 Comment

If we look back just 70 years, the prognosis for patients with haemophilia was remarkably different to what

Capturing progress in haemophilia care

https://pharmaphorum.com/views-and-analysis/capturing-progress-in-haemophilia-care/

News/ News/ R&D

Pfizer, Sangamo resume haemophilia gene therapy trial

Phil Taylor BioMarin Pharmaceuticals, gene therapy, Haematology, haemophilia, haemophilia A, Pfizer, Sangamo Therapeutics 0 Comment

Pfizer and Sangamo have restarted recruitment of patients into their registration trial for haemophilia A gene therapy giroctocogene

Pfizer, Sangamo resume haemophilia gene therapy trial

https://pharmaphorum.com/news/pfizer-sangamo-resume-haemophilia-gene-therapy-trial/

Market Access/ News/ News

Priority review sets up Feb verdict on Sanofi, Sobi haemophilia drug

Phil Taylor BioMarin Pharmaceuticals, haemophilia, Hemlibra, Roche, Sanofi, SOBI 0 Comment

The FDA will carry out a speedy review of Sanofi and Sobi’s once-weekly haemophilia A treatment efanesoctocog alfa

Priority review sets up Feb verdict on Sanofi, Sobi haemophilia drug

https://pharmaphorum.com/news/priority-review-sets-up-feb-verdict-on-sanofi-sobi-haemophilia-drug/

Market Access/ News/ News

Roctavian okay sets up another gene therapy test for Europe

Phil Taylor BioMarin Pharmaceuticals, EU, gene therapy, haemophilia, haemophilia A, regulatory approval, Roctavian 0 Comment

BioMarin Pharma has its landmark first approval for Roctavian – the first for a haemophilia gene therapy –

Roctavian okay sets up another gene therapy test for Europe

https://pharmaphorum.com/news/roctavian-okay-sets-up-another-gene-therapy-test-for-europe/

News/ News/ R&D

Novo Nordisk’s concizumab hits mark in haemophilia, but dosing questioned

Phil Taylor concizumab, haemophilia, Hemlibra, Novo Nordisk, Roche 0 Comment

Novo Nordisk has reported phase 3 results with its concizumab drug for haemophilia A or B, showing efficacy

Novo Nordisk’s concizumab hits mark in haemophilia, but dosing questioned

https://pharmaphorum.com/news/novo-nordisks-concizumab-hits-mark-in-haemophilia-but-dosing-questioned/

News/ News/ R&D

Sanofi trumpets data with haemophilia treatment duo at ISTH

Phil Taylor Alnylam Pharmaceuticals, haemophilia, Hemlibra, Roche, Sanofi, SOBI 0 Comment

Sanofi R&D in its core haemophilia category is advancing on three fronts – engineered proteins, RNA interference drugs

Sanofi trumpets data with haemophilia treatment duo at ISTH

https://pharmaphorum.com/news/sanofi-trumpets-data-with-haemophilia-treatment-duo-at-isth/

News/ News/ R&D

Sanofi/Alnylam’s haemophilia drug hits another safety speed-bump

Richard Staines Alnylam, haemophilia, Rare diseases, Roche, Sanofi 0 Comment

Sanofi’s attempt to take on Roche with a ground-breaking approach to treating haemophilia has hit a setback after

Sanofi/Alnylam’s haemophilia drug hits another safety speed-bump

https://pharmaphorum.com/news/sanofi-alnylans-haemophilia-drug-hits-another-safety-speed-bump/

News/ News/ R&D

Novo Nordisk builds in haemophilia with Bluebird Bio gene editing deal

Phil Taylor bluebird bio, gene editing, genetic, Haematology, haemophilia, Novo Nordisk 0 Comment

Anxious not to be left behind in the haemophilia market, Novo Nordisk has forged an alliance with Bluebird

Novo Nordisk builds in haemophilia with Bluebird Bio gene editing deal

https://pharmaphorum.com/news/novo-nordisk-builds-in-haemophilia-with-bluebird-bio-gene-editing-deal/

Trending

haemophilia

Login